Mario Gaudino

Prof. Dr. Mario Gaudino

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in International Journal of Surgery
Verified
Journal Article
Closed access
NRN. Bryce Robinson
N. Bryce Robinson
KKKatherine Krieger
Katherine Krieger
FKFaiza M. Khan
Faiza M. Khan
WHWilliam Huffman
William Huffman
MCMichelle Chang
Michelle Chang
MGMario Gaudino
Mario Gaudino
Animal models have provided invaluable information in the pursuit of medical knowledge and alleviation of human suffering. The foundations of our basic understanding of disease pathophysiology and human anatomy can largely be attributed to preclinical investigations using various animal models. Recently, however, the scientific community, citing concerns about animal welfare as well as the validity and applicability of outcomes, has called the use of animals in research into question. In this review, we seek to summarize the current state of the use of animal models in research.

31 October 2017 in Circulation
Verified
Journal Article
Closed access
PDF file
MGMario Gaudino
Mario Gaudino
CACharalambos Antoniades
Charalambos Antoniades
UBUmberto Benedetto
Umberto Benedetto
SDSaswata Deb
Saswata Deb
AFAntonino Di Franco
Antonino Di Franco
FBFaisal G. Bakaeen
Faisal G. Bakaeen
Graft failure occurs in a sizeable proportion of coronary artery bypass conduits. We herein review relevant current evidence to give an overview of the incidence, pathophysiology, and clinical consequences of this multifactorial phenomenon. Thrombosis, endothelial dysfunction, vasospasm, and oxidative stress are different mechanisms associated with graft failure. Intrinsic morphological and functional features of the bypass conduits play a role in determining failure. Similarly, characteristics of the target coronary vessel, such as the severity of stenosis, the diameter, the extent of atherosclerotic burden, and previous endovascular interventions, are important determinants of graft outcome and must be taken into consideration at the time of surgery. Technical factors, such as the method used to harvest the conduits, the vasodilatory protocol, the storage solution, and the anastomotic technique, also play a major role in determining graft success. Furthermore, systemic atherosclerotic risk factors, such as age, sex, diabetes mellitus, hypertension, and dyslipidemia, have been variably associated with graft failure. The failure of a coronary graft is not always correlated with adverse clinical events, which vary according to the type, location, and reason for failed graft. Intraoperative flow verification and secondary prevention using antiplatelet and lipid-lowering agents can help reducing the incidence of graft failure.

31 January 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MGMario Gaudino
Mario Gaudino
AFAntonino Di Franco
Antonino Di Franco
LRLisa Rong
Lisa Rong
JPJonathan Piccini
Jonathan Piccini
MMMichael Mack
Michael Mack
Postoperative atrial fibrillation (POAF) is the most common type of secondary atrial fibrillation (AF) and despite progress in prevention and treatment, remains an important clinical problem for patients undergoing a variety of surgical procedures, and in particular cardiac surgery. POAF significantly increases the duration of postoperative hospital stay, hospital costs, and the risk of recurrent AF in the years after surgery; moreover, POAF has been associated with a variety of adverse cardiovascular events (including stroke, heart failure, and mortality), although it is still unclear if this is due to causal relation or simple association. New data have recently emerged on the pathophysiology of POAF, and new preventive and therapeutic strategies have been proposed and tested in randomized trials. This review summarizes the current evidence on the pathogenesis, incidence, prevention, and treatment of POAF and highlights future directions for clinical research.

14 July 2020 in JAMA
Verified
Journal Article
Open access
PDF file
MGMario Gaudino
Mario Gaudino
UBUmberto Benedetto
Umberto Benedetto
SFStephen Fremes
Stephen Fremes
KBKarla Ballman
Karla Ballman
GBGiuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai
FIfor the RADIAL Investigators
for the RADIAL Investigators
The long-term clinical consequences of using the radial artery instead of the saphenous vein for coronary artery bypass grafting (CABG) remain uncertain. Observational studies have suggested that the use of the radial artery is associated with better postoperative outcomes,1 but they are open to bias.2

20 October 2017 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
MGMario Gaudino
Mario Gaudino
JAJohn H Alexander
John H Alexander
FBFaisal G Bakaeen
Faisal G Bakaeen
KBKarla Ballman
Karla Ballman
FBFabio Barili
Fabio Barili
SFStephen Fremes
Stephen Fremes
The primary hypothesis of the ROMA trial is that in patients undergoing primary isolated non-emergent coronary artery bypass grafting, the use of 2 or more arterial grafts compared with a single arterial graft (SAG) is associated with a reduction in the composite outcome of death from any cause, any stroke, post-discharge myocardial infarction and/or repeat revascularization. The secondary hypothesis is that in these patients, the use of 2 or more arterial grafts compared with a SAG is associated with improved survival. The ROMA trial is a prospective, unblinded, randomized event-driven multicentre trial comprising at least 4300 subjects. Patients younger than 70 years with left main and/or multivessel disease will be randomized to a SAG or multiple arterial grafts to the left coronary system in a 1:1 fashion. Permuted block randomization stratified by the centre and the type of second arterial graft will be used. The primary outcome will be a composite of death from any cause, any stroke, post-discharge myocardial infarction and/or repeat revascularization. The secondary outcome will be all-cause mortality. The primary safety outcome will be a composite of death from any cause, any stroke and any myocardial infarction. In all patients, 1 internal thoracic artery will be anastomosed to the left anterior descending coronary artery. For patients randomized to the SAG group, saphenous vein grafts will be used for all non-left anterior descending target vessels. For patients randomized to the multiple arterial graft group, the main target vessel of the lateral wall will be grafted with either a radial artery or a second internal thoracic artery. Additional grafts for the multiple arterial graft group can be saphenous veins or supplemental arterial conduits. To detect a 20% relative reduction in the primary outcome, with 90% power at 5% alpha and assuming a time-to-event analysis, the sample size must include 845 events (and 3650 patients). To detect a 20% relative reduction in the secondary outcome, with 80% power at 5% alpha, the sample size must include 631 events (and 3650 patients). To be conservative, the sample size will be set at 4300 patients. The primary outcome will be tested according to the intention-to-treat principle. The primary analysis will be a Cox proportional hazards regression model, with the treatment arm included as a covariate. If non-proportional hazards are observed, alternatives to Cox proportional hazards regression will be explored.

1 December 2021 in The Lancet
Verified
Journal Article
Closed access
MGMario Gaudino
Mario Gaudino
TSTommaso Sanna
Tommaso Sanna
KBKarla V Ballman
Karla V Ballman
NRN Bryce Robinson
N Bryce Robinson
IHIrbaz Hameed
Irbaz Hameed
LGLeonard Girardi
Leonard Girardi